|Bid||0.0000 x 800|
|Ask||0.0000 x 900|
|Day's Range||4.8400 - 5.0800|
|52 Week Range||4.5800 - 32.0000|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.67|
Subscribe to Yahoo Finance Plus to view Fair Value for ADCT
LAUSANNE, Switzerland, September 21, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), which will be held in Houston, Texas from September 28–October 1, 2022.
LAUSANNE, Switzerland, September 16, 2022--ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The positive opinion from the CHMP is now referred to the European Commission for an
LAUSANNE, Switzerland, September 06, 2022--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20th Annual Global Healthcare Conference on Tuesday, September 13th at 11:45 a.m. ET.